8-K: Celularity Enters Strategic Collaboration with BlueSphere Bio for Cell Therapy Manufacturing

Celularity Inc. announces a Master Services Collaboration Agreement with BlueSphere Bio, Inc. for manufacturing activities related to BSB's cell therapy products.

Summary

• Celularity Inc. has entered into a Master Services Collaboration Agreement with BlueSphere Bio, Inc. (BSB) for manufacturing BSB's cell therapy products.
• This is Celularity's second collaboration of this kind, highlighting its cGMP manufacturing infrastructure and expertise.
• The collaboration will initially focus on producing BSB's T cell receptor (TCR) T cell therapies at Celularity's Florham Park, NJ facility.
• Celularity will dedicate staff and a portion of its 37,000 square foot commercial manufacturing footprint to the collaboration.
• BSB will have oversight over the production of its second cell therapy product for Acute Myelogenous Leukemia (AML) in the U.S. and abroad.
• BlueSphere Bio anticipates dosing its first patient in the TCX-101 program in 1H2025.
• An IND is expected in the second quarter of 2025 for the TCX-102 program.

Sentiment

Score: 7

Explanation: The announcement is positive as it signifies a new revenue stream and validates Celularity's manufacturing capabilities. However, it's important to note the forward-looking statements and potential risks associated with the collaboration.

Positives

• The collaboration demonstrates Celularity's ability to attract clients seeking differentiated manufacturing alternatives.
• The agreement has the potential to generate revenue for Celularity.
• BSB gains access to Celularity's manufacturing capabilities to advance its cell therapy programs.
• The collaboration allows BSB to advance its assets to the clinic in an affordable fashion, without relinquishing control over its processes.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• Actual results could differ materially from those described in the forward-looking statements due to various factors, including those outlined in Celularity's SEC filings.

Future Outlook

The collaboration aims to leverage Celularity's manufacturing infrastructure to support BSB's development of novel cell therapies and potentially attract future clients seeking GMP manufacturing needs.

Management Comments

• Robert J. Hariri, M.D., Ph.D., Celularity CEO and Chair, stated that the collaboration will bring together core strengths in cell manufacturing, process development, and BSB's development of novel cell therapies.
• Keir Loiacono, CEO of BlueSphere, noted that Celularity's business model and facility will provide BlueSphere with the necessary tools to advance its assets to the clinic in an affordable fashion.

Industry Context

This collaboration reflects a growing trend in the cell therapy industry where companies are outsourcing manufacturing to specialized facilities to reduce costs and accelerate development timelines. Celularity is positioning itself as a key player in this space by offering its cGMP manufacturing capabilities to other companies.

Comparison to Industry Standards

• Celularity's strategy of offering its manufacturing capabilities to other companies is similar to that of companies like Lonza and WuXi AppTec, which provide contract development and manufacturing services to the pharmaceutical and biotech industries.
• The 37,000 square foot facility is a significant asset, comparable to other cGMP manufacturing facilities used for cell therapy production.
• The focus on cell therapy manufacturing for companies like BlueSphere Bio is in line with the industry's increasing demand for specialized manufacturing capabilities.

Stakeholder Impact

• Shareholders may view the collaboration positively as it represents a potential revenue stream and validates Celularity's business model.
• Employees at Celularity's Florham Park facility will be involved in the manufacturing of BSB's cell therapies.
• The collaboration could lead to the development of new therapies for patients with Acute Myelogenous Leukemia (AML).

Next Steps

• Celularity and BSB will begin manufacturing BSB's TCR T cell therapies at Celularity's Florham Park facility.
• BSB anticipates dosing its first patient in the TCX-101 program in 1H2025.
• An IND is expected in the second quarter of 2025 for the TCX-102 program.

Key Dates

Keywords

cell therapy, manufacturing, collaboration, Celularity, BlueSphere Bio, cGMP, AML, TCR T cell therapies